Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 2015-2022

  Wang, Benquan ^a   Zou, Qian ^a   Sun, Meng ^a   Chen, Jingfeng ^a   Wang, Tianyang ^a   Bai, Yongheng ^a   Chen, Zongjing ^a   Chen, Bicheng ^a   Zhou, Mengtao ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Epithelial mesenchymal transition; Pancreatic cancer; Trichostatin A; Wnt catenin signaling pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN; WNT C59; WNT PROTEIN; 2-(4-(2-METHYLPYRIDIN-4-YL)PHENYL)-N-(4-(PYRIDIN-3-YL)PHENYL)ACETAMIDE; BENZENEACETAMIDE DERIVATIVE; HYDROXAMIC ACID; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MDR1 GENE; MULTIDRUG RESISTANCE; PANC 1 CELL LINE; PANCREAS CANCER; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; CELL MOTION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BENZENEACETAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; PANCREATIC NEOPLASMS; PYRIDINES; WNT SIGNALING PATHWAY;

EID: 84907293657     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3476     Document Type: Article

References (44)

1. Akita H, Doki Y, Miyata H, et al: Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 93: 401-409, 2006.
2. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 21: 313-320, 2009.
3. Batova A, Shao LE, Diccianni MB, et al: The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drugresistant primary leukemia and cancer cell lines. Blood 100: 3319-3324, 2002.
4. Bordonaro M, Tewari S, Cicco CE, Atamna W and Lazarova DL: A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One 6: e27308, 2011.
5. Fournel M, Trachy-Bourget MC, Yan PT, et al: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62: 4325-4330, 2002.
6. Freese JL, Pino D and Pleasure SJ: Wnt signaling in development and disease. Neurobiol Dis 38: 148-153, 2010.
7. Ganesan A, Nolan L, Crabb SJ and Packham G: Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9: 963-981, 2009.
8. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
9. Greenhalf W and Thomas A: Combination therapy for the treatment of pancreatic cancer. Anticancer Agents Med Chem 11: 418-426, 2011.
10. Griesmann H, Ripka S, Pralle M, et al: WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 15: 11-22, 2013.
11. Grimm M, Lazariotou M, Kircher S, et al: MMP-1 is a (pre-) invasive factor in Barrett-Associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 8: 99, 2010.
12. Hidalgo M and von Hoff DD: Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 18: 4249-4256, 2012.
13. Hong Y, Yang J, Wu W, et al: Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 1782: 649-657, 2008.
14. Hung CC and Liou HH: YC-1, a novel potential anticancer agent, inhibits multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 29: 1337-1346, 2011.
15. Inman GJ, Nicolas FJ, Callahan JF, et al: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74, 2002.
16. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV and Korc M: Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505-3511, 1999.
17. Le X, Shi Q, Wang B, et al: Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20: 935-946, 2000.
18. Li Y, Van den Boom TG II, Kong D, et al: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712, 2009.
19. Liu X, Mazanek P, Dam V, et al: Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27: 1478-1488, 2008.
20. Liu Yong FY and Wang Hui: Synergistic augmentation of cisplatin-induced apoptosis in HeLa cells by rapamycin. Central China Med J 33: 300-303, 2009.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
22. Long J, Zhang Y, Yu X, et al: Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 15: 817-828, 2011.
23. Loos M, Kleeff J, Friess H and Büchler MW: Surgical treatment of pancreatic cancer. Ann NY Acad Sci 1138: 169-180, 2008.
24. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM and Kitajewski J: Wnt/beta-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 8: 43-51, 2005.
25. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006.
26. Mellor HR and Callaghan R: Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81: 275-300, 2008.
27. Mimeault M, Hauke R and Batra SK: Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83: 673-691, 2008.
28. Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S and Batra SK: MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett 295: 69-84, 2010.
29. Moore PS, Barbi S, Donadelli M, et al: Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro-And antiapoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 1693: 167-176, 2004.
30. Nakagami H, Soukupova H, Schikora A, Zarsky V and Hirt H: A Mitogen-Activated protein kinase mediates reactive oxygen species homeostasis in Arabidopsis. J Biol Chem 281: 38697-38704, 2006.
31. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304: 1073-1081, 2010.
32. Osborn MT and Chambers TC: Role of the stress-Activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955, 1996.
33. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G and Beger HG: Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 95: 194-197, 2001.
34. Rocchi E, Khodjakov A, Volk EL, et al: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 271: 42-46, 2000.
35. Sayat R, Leber B, Grubac V, Wiltshire L and Persad S: O-GlcNAc.glycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. Exp Cell Res 314: 2774-2787, 2008.
36. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine.resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
37. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
38. Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127: 555-567, 2010.
39. Vaccaro V, Melisi D, Bria E, et al: Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 15: 1183-1196, 2011.
40. van Hinsbergh VW, Engelse MA and Quax PH: Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26: 716-728, 2006.
41. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
42. Yao J, Cai HH, Wei JS, et al: Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep 23: 1375-1382, 2010.
43. Yochum GS, Sherrick CM, Macpartlin M and Goodman RH: A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA 107: 145-150, 2010.
44. Yuan RH, Jeng YM, Hu RH, et al: Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg 15: 321-329, 2011.